Abstract:BACKGROUND: Bioartificial liver support systems are becoming an effective therapy for hepatic failure. Bioreactors, as key devices in these systems, can provide a favorable growth and metabolic environment, mass exchange, and immunological isolation as a platform. Currently, stagnancy in bioreactor research is the main factor restricting the development of bioartificial liver support systems. DATA SOURCES: A PubMed database search of English-language literature was performed to identify relevant articles using the keywords "bioreactor", "bioartificial liver", "hepatocyte", and "liver failure". More than 40 articles related to the bioreactors of bioartificial livers were reviewed. RESULTS: Some progress has been made in the improvement of structures, functions, and modified macromolecular materials related to bioreactors in recent years. The current data on the improvement of bioreactor configurations for bioartificial livers or on the potential of the use of certain scaffold materials in bioreactors, combined with the clinical efficacy and safety evaluation of cultured hepatocytes in vitro, indicate that the AMC (Academic Medical Center) BAL bioreactor and MELS (modular extracorporeal liver support) BAL bioreactor system can partly replace the synthetic and metabolic functions of the liver in phase I clinical studies. In addition, it has been indicated that the microfluidic PDMS (polydimethylsiloxane) bioreactor, or SlideBioreactor, and the microfabricated grooved bioreactor are appropriate for hepatocyte culture, which is also promising for bioartificial livers. Similarly, modified scaffolds can promote the adhesion, growth, and function of hepatocytes, and provide reliable materials for bioreactors. CONCLUSIONS: Bioreactors, as key devices in bioartificial livers, play an important role in the therapy for liver failure both now and in the future. Bioreactor configurations are indispensable for the development of bioartificial livers used for liver failure, just as the modified scaffold materials available for bioreactors are favorable to the construction of effective bioartificial livers.

Clinical translation of bioartificial liver support systems with human pluripotent stem cell-derived hepatic cells

Advances in cell sources of hepatocytes for bioartificial liver.

Key Challenges to the Development of Extracorporeal Bioartificial Liver Support Systems

In VitroandIn VivoHepatic Differentiation of Adult Somatic Stem Cells and Extraembryonic Stem Cells for Treating End Stage Liver Diseases

[Current Status and Perspectives of Artificial Liver for Treatment of Acute-on-chronic Liver Failure].

Pluripotent Stem Cell-derived Strategies to Treat Acute Liver Failure: Current Status and Future Directions.

Progress in bioreactors of bioartificial livers.

Therapeutic Cell Repopulation of the Liver: From Fetal Rat Cells to Synthetic Human Tissues

A new cell source for bioartificial liver support system-induced pluripotent stem cell

[Bioartificial Liver Support System: State of the Art].

Challenges on the road to a multicellular bioartificial liver

Stem Cell-Based Strategies: The Future Direction of Bioartificial Liver Development

Bioinspired Artificial Liver System with hiPSC‐Derived Hepatocytes for Acute Liver Failure Treatment

Assembly and Function of a Bioengineered Human Liver for Transplantation Generated Solely from Induced Pluripotent Stem Cells.

Systematic Review: Extracorporeal Bio-Artificial Liver-Support System for Liver Failure

Development of a Novel Artificial Liver Support System

Bioartificial Liver Devices: Perspectives on the State of the Art

In Vitro and In Vivo Hepatic Differentiation of Adult Somatic Stem Cells and Extraembryonic Stem Cells for Treating End Stage Liver Diseases

Co-culture of Parenchymal and Non-Parenchymal Liver Cells and Non-Liver-derived Cells

Advances in Cell Components of Bioartificial Liver

iPSC-derived cells for whole liver bioengineering